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Weakly tumorigenic and nonmetastatic QR-32 cells derived from a fibrosarcoma in C57BL6 mouse are converted to malignant cells
once they have grown after being coimplanted with a gelatine sponge which induces inflammation. We administered a newly
developed peroral superoxide dismutase (SOD), oxykine, and as control vehicle, gliadin and saline, starting 2 days before the
coimplantation and continued daily throughout the experiment. In the oxykine group, tumour incidence was lower (41%) than in the
gliadin or saline group (83 and 79%, respectively). The inhibitory effect of oxykine was lost when an individual component of oxykine
was administered, that is, SOD alone and gliadin alone. The effect was also abolished when administered by intraperitoneal route.
When perfused in situ with nitroblue tetrazolium, an indicator of superoxide formation, the tumour masses from gliadin and saline
groups displayed intense formazan deposition, whereas, those from oxykine group had less deposition. Enzymatic activity of SOD was
also increased in oxykine group. Arising tumour cells in gliadin and saline groups acquired metastatic phenotype, but those in oxykine
group showed reduced metastatic ability. These results suggested that the orally active SOD derivative prevented tumour
progression promoted by inflammation, which is thought to be through scavenging inflammatory cell-derived superoxide anion.
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Evidence has been accumulated that many of the cell alterations
seen in normal ageing and in various diseases including cancer are
due to oxidative damage by active oxygen species (Taniguchi,
1992). Oxygen radicals are a by-product of aerobic respiration and
harmful to living cells (Halliwell et al, 1992). In tumour tissues,
oxygen radicals are generated by cancer cells themselves
(Shaughnessy et al, 1989; Szatrowski and Nathan, 1991; Oberley
and Oberley, 1997), and infiltrating inflammatory cells such as
neutrophils (Babior et al, 1973; Weissmann et al, 1980) are
believed to exert tumoricidal effects at their relatively high
concentrations. On the other hand, the normal or premalignant
cells which are chronically exposed to or escape from a highly
cytotoxic concentration of oxygen radicals tend to be transformed
to malignant ones or acquire malignant properties as evidenced
under certain conditions; namely, oxygen radicals stimulate
tumour cell invasion (Shinkai et al, 1986) or enhance metastasis
(Orr et al, 1988).
Most aerobic cells have an enzymatic system to eliminate active
oxygen species, because some of these active species are toxic to
host. Superoxide dismutases (SODs), catalase, and glutathione
peroxidase comprise the major defence system against oxygen
toxicity (McCord and Fridovich, 1969). Superoxide dismutases
catalyse the dismutation of superoxide anion (O2
 ) to produce
hydrogen peroxide and O2. Superoxide anion is one of the reduced
oxygen species generated in cellular metabolism or produced by
inflammatory cells at their respiratory burst.
There are three isozymes of SODs in mammalian system
(Taniguchi, 1992). Among them, manganese-SOD (manganese-
superoxide dismutase (Mn-SOD)) and copper, zinc-SOD (Cu,Zn-
SOD) are widely believed to play an important role in carcinogenic
processes (Oberley and Buettner, 1979; Dovrat and Gerhon, 1981).
It has been found that tumour cells tend to have reduced activities
of those SODs compared to normal counterpart (Sykes et al, 1978;
Oberley and Buettner, 1979; St Clair and Holland, 1991; Brorrello
et al, 1993), and overexpression of SOD decreases malignant
phenotypes in various cancers including breast cancer (Li et al,
1995), melanoma (Chruch et al, 1993) and glioma (Zhong et al,
1997). Moreover, it is known that levels of SODs inversely correlate
with metastatic ability of tumour cells (Kwee et al, 1991), and that
SOD suppresses metastasis of tumour cells in vivo (Safford et al,
1994; Yoshizaki et al, 1994) and inhibits their motility and
invasiveness (Muramatsu et al, 1995). Superoxide dismutase
also acts as differentiation inducer for erythroleukaemia cells
(Beckman et al, 1989). In other words, deficiency of SOD may
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sdisturb redox status in cells, which influences neoplastic
transformation and/or the maintenance of the malignant pheno-
type (Oberley and Buettner, 1979; Loven et al, 1984; Oberley and
Oberley, 1988). In fact, in vitro transformation of normal fibroblast
cell lines was carried out by infection with simian virus 40 (SV40)
for comparing SOD amounts before and after transformation
(Marlhens et al, 1985; Oberley et al, 1989). The results showed that
all of the SV40-transformed cell lines decreased the SOD amount as
compared to the original normal fibroblast cell line. Recently,
enforced expression of SOD in SV40-transformed cells partially
reversed their malignant phenotypes (Yan et al, 1996). Also,
constitutively expressed high levels of SOD in mouse C3H10T1/2
cells coincided with a decrease in the frequency of radiation-
induced neoplastic transformation (St Clair et al, 1992). Since an
inverse correlation thus exists between its expression and tumour
development and progression (Safford et al, 1994), it has been
hypothesised that SOD is a new tumour suppressor gene (Bravard
et al, 1992).
Introduction of SODs into tumour cells and/or tumour tissues
is theoretically the most efficient strategy for inhibiting both
tumour growth and progression. However, for induction of
appropriate levels of SOD, it is necessary to use specialised
techniques, for example, DNA transfection methods or modifica-
tion of a specific amino-acid sequence of SOD or modification of
SOD to make it stable after injection in vivo. It would be beneficial
to develop peroral active SOD for wide preclinical usage. In this
scheme, Giri and Misra (1984) have reported that, similarly to
most proteins, orally administered SOD will be digested in the
stomach and only a small portion of SOD will be absorbed in
the blood stream through gastrointestinal tract. For minimising
the digestion, SOD has been coated with a wheat-based
biopolymer, gliadin, (Triticum vulgare, Poaceae) which not only
prevents gastric digestion (Vouldoukis et al, 2003) but also
promotes the delivery of the bioactive molecules into the small
intestinal mucosa by enhancing the intestinal permeability through
activation of a tight-junction-regulating protein, zonulin
(Clemente et al, 2003).
Our group previously showed that the QR tumour cells obtained
from a clonal murine fibrosarcoma were unable to grow in normal
syngeneic C57BL/6 mice when injected subcutaneously (2 10
5)
whereas they developed tumours after coimplantation with a
foreign body, gelatine sponge (Okada et al, 1992). We reasoned
that the foreign-body-induced inflammation accelerated the
progression of QR tumour cells, and suggested the involvement
of active oxygen species produced by inflammatory cells in this
process (Okada et al, 1999; Tazawa et al, 2003). The QR-32 tumour
cells used in the present study were most sensitive to inflamma-
tion-promoted progression, as compared to other QR tumour
clones with resistance to progression, since they had significantly
decreased Mn-SOD activity (Okada et al, 1999). For this reason, we
used the tumour cell line for evaluation of the newly developed
SOD derivative, oxykine, in prevention of active oxygen species-
mediated tumour progression.
We aimed to determine the potential inhibitory effect of oxykine
in the model in which we can observe both tumour formation
(primary tumour) and progression of tumour cells (acquisition of
metastatic phenotype). We herein reported that oxykine reduced
primary tumour growth and prevented the acquisition of
metastatic property of tumour cells through suppression of
superoxide anion at the tumour-growing sites.
MATERIALS AND METHODS
Chemicals
Oxykine
s, melon-derived SOD and gliadin were provided by
Asama Chemical Inc., Tokyo, Japan. The SOD activity of oxykine
was 1000Ug
 1. It was diluted with PBS just before usage and kept
on ice until administration. The dose was fixed at 10mgkg
 1, and
administered intragastrically.
Tumour cell lines and culture conditions
The origin and characteristics of the tumour cell lines have been
described previously (Ishikawa et al, 1987). Briefly, BMT-11, a
transplantable fibrosarcoma, was induced in a C57BL/6 mouse
with 3-methyl-cholanthrene, and a tumorigenic clone BMT-11 cl-9
was subsequently isolated by limiting dilution. BMT-11 cl-9 cells
were exposed in vitro to quercetin, which gave rise to a number of
random subclones (Ishikawa et al, 1987). They spontaneously
regressed when injected into normal syngeneic mice. The variants
were named ‘QR tumour clones’, representing ‘quercetin-induced
regressive tumour’. Tumour cells of one of the variant cell clones,
QR-32, were used in this study. The culture cell lines established
from tumours arisen after coimplantation of QR-32 tumour cells
with gelatine sponge in mice were designated as ‘QRsP’,
representing ‘progressive tumour variants derived from QR-32
tumour cells co-implanted with gelatine sponge’. The QR-32
tumour cells and QRsP tumour cell lines were maintained in
Eagles’s minimum essential medium (MEM, Nissui Pharm., Japan)
supplemented with 8% fetal bovine serum (Filtron), sodium
pyruvate, nonessential amino acids and L-glutamine, at 371C, in
a humidified 5% CO2/95% air mixture.
Mice
Female C57BL/6 mice (5 weeks old) were obtained from Nippon
SLC (Hamamatsu, Japan) and used for the experiments. All the
mice were maintained in the complete barrier condition, lit from
0700 to 1900, at 23 31C and 50 10% humidity, fed with mouse
diet (Nihon Nosan Kogyo, Yokohama, Japan) and UV-irradiated
water in the germ-free section of Institute for Animal Experi-
mentation, Hokkaido University Graduate School of Medicine.
Diet and tap water were available ad libitum throughout the
experiment.
Experimental procedures
The experimental protocol was approved by the Committee of
Institute for Animal Experimentation, Hokkaido University
Graduate School of Medicine (#01139).
The mice at 6 weeks of age were used after 1 week of
acclimatisation. A subcutaneous pocket reaching up to the thorax
was made from a 10mm incision on the right flank of the pelvic
region in each anaesthetised mouse and one piece of sterile
gelatine sponge (10 5 3mm
3 piece; Spongel, Yamanouchi
Pharm., Japan) was inserted and the wound was closed with clips.
Then QR-32 tumour cells (1 10
5 cells/0.1ml) were immediately
injected into the inserted gelatine sponge (Okada et al, 1992).
The mice were divided randomly into three groups and treated
with oral administration of oxykine or gliadin at a dose of
10mgkg
 1 body weight, or saline. The treatment was carried out
every day from 2 days before QR-32 tumour cell implantation to
the end of the experiment. Tumour diameter and body weight were
measured twice a week during the experiment. All the mice were
killed under ether anaesthesia at 28 days after implantation for
evaluation of the arising tumours’ malignancy and autopsy;
simultaneously we removed the subcutaneously growing tumours
aseptically to assess whether the arising tumours had acquired
malignant phenotype, and used them for establishing individual
culture cell lines after mechanical disaggregation with scissors. The
detailed procedure has been described elsewhere (Okada et al,
1992). The tumour lines were allowed at least four passages in
culture to eliminate host cell contamination. Each tumour cell line
was injected intravenously (1 10
6 cells) into normal C57BL/6
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smice. On day 25, the mice were killed and metastatic nodules
at the surface of the lungs or other organs were counted
macroscopically.
Determination of the total number and the types of the
cells infiltrated into gelatin sponge
The gelatin sponge pieces subcutaneously injected into the mice
treated with oxykine, gliadin, melon-SOD or saline were removed
and digested with 0.2% collagenase in serum-free MEM medium
for a few minutes at 371C. After collecting all the infiltrated cells by
centrifugation, we counted total number of the cells per piece of
gelatin sponge. We also counted differential counts of more than
200 cells in smear preparations of the collected cells stained with
May-Gruenwald’s and Giemsa solution (Wako Pure Chemical Inc.,
Osaka, Japan). Mean percentages of differential cells were obtained
from the mean values of independent counts by two pathologists.
Nitroblue tetrazolium (NBT) staining
The mice were killed by cervical dislocation, and the tumour
masses were excised and simultaneously stained for a few minutes
with NBT (1mgml
 1) in Hank’s balanced salt solution (HBSS;
24020-117, Invitrogen, Tokyo, Japan). All unreacted NBT was
removed from the tumour masses by washing with HBSS.
The NBT-perfused tumour mass was photographed and then
fixed with 10% (wtvol
 1) zinc/formalin for histologic examination
of formazan deposits. The procedure followed the method
described in a previous paper with slight modifications (Hagen
et al, 1994).
Assay for enzymatic activities
The methods for evaluating enzymatic activities have been
described previously (Okada et al, 1999). Briefly, the tumour
tissues were washed with PBS and homogenised in liquid nitrogen.
The homogenates were suspended in the PBS and then sonicated
on ice four times, for 10s each, by using a sonicator at intensity of
4 (Microson, Wakenyaku Co. Ltd., Kyoto, Japan). The homo-
genates were centrifuged at 15000rpm for 15min and the resulting
supernatant was used for enzymatic assay. Serum samples were
diluted with PBS and used.
Superoxide dismutase activity was measured by the NBT
reduction method (Beauchamp and Fridovich, 1971), with slight
modifications. Manganese-superoxide dismutase activity was
examined at 251C in 1ml of 20mM sodium carbonate buffer, pH
10, containing 0.1mM EDTA, 0.2mM xanthine, 12mM NBT and
1.9mU xanthine oxidase, and determined from the remaining SOD
activity after addition of 2mM potassium cyanide with a spectro-
meter at 560nm. The amount of enzyme-reducing NBT by 50%
was defined as one unit of SOD activity. Catalase activity was
measured from decomposition of hydrogen peroxide, which was
recorded at 230nm on a chart recorder for 1min at 361C.
Glutathione peroxidase (GPx) activity was determined by using a
b-butyl hydroperoxide as substrate. One unit of the enzyme
activity was defined as 1mmol NADPH oxidisedmin
 1 at 361C. The
enzyme activities of Mn-SOD, CuZn-SOD, catalase and GPx were
expressed as Umg
 1 protein. Protein concentration was estimated
by the Lowry method (Lowry et al, 1951).
Statistical analysis
The significance of the differences in tumour and metastatic
incidences was calculated by w
2 test and the differences in
metastatic nodules or body and organ weight were evaluated by
Student’s t-test.
RESULTS
Inhibition of growth of QR-32 tumour cells coimplanted
with gelatine sponge in syngeneic mice treated with
oxykine
Benign fibrosarcoma cells (QR-32) did not develop tumours or form
metastasis after subcutaneous (2 10
5 cells) or intravenous (1 10
6
cells) injection into normal syngeneic C57BL/6 mice (Ishikawa et al,
1987). Table 1a shows that QR-32 tumour cells coimplanted with a
gelatine sponge grew in 15 out of 19 saline-treated mice (79%), 15
out of 18 gliadin-treated mice (83%) and 10 out of 17 oxykine-
treated mice (59%). We did not find any significant difference in the
tumour incidence among the three groups. However, in an attempt
to establish tumour cell lines from the arising tumours, we failed in
three out of the 10 tumours arisen in oxykine-treated mice due to
scar or necrotic tissues, none of which were viable tumours as far as
examined macroscopically and histologically (data not shown).
Namely, the number of established cell lines (which is equivalent to
the final incidence of tumour formation) was significantly reduced
in the oxykine-treated mice compared to those in saline- or gliadin-
treated mice (P40.05, Table 1a).
Tumour growth curves of the arising tumours are shown in
Figure 1A. Oxykine administration had a slight inhibitory effect on
the tumour growth, though it was not significant.
Inhibition of oxidant production by oxykine treatment at
the inflammation-promoted tumour formation
Nitroblue tetrazolium is a dye that is reduced to an insoluble
formazan derivative upon exposure to superoxide (Halliwell and
Gutteridge, 1999). The blue-coloured formazan crystal deposition
was extensively detectable at the surface of tumour tissues from
gliadin- or saline-treated mice. In contrast, tumour tissue from the
oxykine-treated mice had less deposit of the crystal (Figure 2A).
We performed histological examination and revealed intense
deposition of formazan crystal around the gelatine sponge
filament, which coincided with the presence of infiltrated
inflammatory cells. The density of formazan deposits also reflected
the amount of superoxides generated locally. Namely, formazan
staining was evident in gliadin-treated tumour tissues (Figure 2B),
and, less in oxykine-treated tissues (Figure 2C). These results
indicated that tumour tissues in oxykine-treated mice contained
lower concentrations of oxygen radicals.
We then examined reactive oxygen species (ROS) statuses in
both tumour cells and the inflammatory cells both of which had
infiltrated into gelatin sponge. After harvesting those cells by
collagenase digestion, we compared cytosolic ROS levels by using
an ROS probe, 5-(and-6)-chloromethyl-20,7 0-dichlorodihydro-
fluorescein diacetate (CM-H2DCFDA) and measured intracellular
ROS levels by flow cytometry. Mean fluorescence intensities of the
cells harvested from the gelatin sponge in the mice orally treated
with oxykine, melon-SOD (main component of oxykine), gliadin
or saline were 37.4 8.6, 42.5 13.6, 49.9 22.2, 47.5 14.2,
respectively. We detected positive tendency to decrease the
production of ROS in the oxykine-treated group as compared to
those in other groups; however, the difference was not significant.
We then compared the antioxidative enzyme activities such as
those of SOD, glutathione peroxidase and catalase in the serum or
tumour tissues after oral administration of oxykine, gliadin or
melon-SOD (Table 2). We found that a significant increase in Mn-
SOD activity in the tumour tissues from the mice with orally
administered oxykine. Since either of the components of oxykine,
that is, melon-derived SOD or gliadin, does not have the ability to
induce Mn-SOD by itself, the oxykine formulation composed of
melon-derived SOD and covered with gliadin was thought
necessary to induce preventive effects on the inflammation-
induced tumour progression.
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sOral administration is necessary for inhibiting tumour
development and acquisition of metastatic phenotype of
the QR-32 cells
When we administered oxykine, melon-SOD, gliadin or saline to
mice via intraperitoneal route, the effect of oxykine as observed in
peroral administration was lost (Table 3). This finding indicated
that the inhibition of tumour progression depends on the
formulation of the compound and the route of administration.
The inhibitory effect of peroral administration of oxykine was also
explained by the capacity to have an antioxidative enzyme, SOD, in
tumour cells since the oral administration of oxykine-induced SOD
in tumour tissues. However, the effect was abolished by switching
the administration route to intraperitoneal route (Table 2).
Inhibition of QRsP/OK tumour lines’ acquisition of lung
metastatic ability by oxykine
It is the advantage of this model that we can determine whether
the arising tumour cells acquire metastatic ability without
Table 1 Inhibition of tumour development and acquisition of metastatic ability of QR-32 tumour cells by administration of oxykine (a) tumorigenicity of
QR-32 cells co-implanted with gelatin sponge in mice and (b) characteristics of the arising tumour lines
No. of mice with tumour take/no, of mice treated (%)
Treated with
a Exp. 1 Exp. 1 Total
No. of cell lines establihed/
no of tumours tested (%)
b
(a) Tumorigenicity of QR-32 cells co-implanted with gelatin sponge in mice
—— — — —
Saline 8/9 (89) 7/10 (70) 15/19 (79) 15/19
c (79)
Gliadin 8/8 (100) 7/10 (70) 15/18 (83) 15/18 (83)
Oxykine 4/7 (57) 6/10 (60) 10/17 (59) 7/17
c (41)
Lung-colonising ability Other metastasis sites
Cell lines established from
the arising tumour
Incidence (no. of mice
with lung metastasis/no. of
mice tested)
No. of lung with
metastatic nodules
Incidence no. of mice with
other metastases/no of
mice tested)
Sites (incidence)
(b) Characteristics of the arising tumour lines
d
QR-32 0/10 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 0/10 None
QRsP/-1 3/3 1, 3, 14 0/3 None
QRsP/-2 3/3 8, 13, 20 0/3 None
QRsP/-3 4/4 3, 8, 14, 4150 1/4 [O (1/4)]
QRsP/-4 3/4 0, 1, 3, 35 0/4 None
QRsP/-5 4/5 0, 2, 7, 8, 15 1/5 [O (1/5)]
QRsP/-6 4/4 8, 43, 4150, 4150 2/4 [O (2/4)]
QRsP/-7 4/4 8, 11, 4150, 4150 2/4 [O (2/4)]
QRsP/-8 4/4 4150, 4150, 4150, 4150 0/4 None
QRsP/-9 4/4 16, 48, 51, 62 0/4 None
Total 33/35
e 6/35 None
QRsP/GD-1 4/4 2, 2, 4, 17 0/4 None
QRsP/GD-2 4/4 5, 6, 12, 14 0/4 None
QRsP/GD-3 2/4 0,0,3,8 0/4 None
QRsP/GD-4 3/4 0, 5, 7, 22 1/4 [O (1/4)]
QRsP/GD-5 3/4 0, 3, 6, 12 0/4 None
QRsP/GD-6 4/4 2, 5, 6, 7 1/4 [O (1/4)]
QRsP/GD-7 3/3 16, 4150, 4150 1/3 [O (1/3), A (1/3)]
QRsP/GD-8 4/4 25, 58, 132, 4150 3/4 [O (2/4), LN(1/4]
QRsP/GD-9 4/4 58, 73, 4150, 4150 0/4 None
QRsP/GD-10 4/4 42, 43, 123, 4150 0/4 None
Total 35/39 5/39 None
QRsP/OK-1 0/4 0, 0, 0, 0 0/4 None
QRsP/OK-2 3/4 0, 2, 3, 18 0/4 None
QRsP/OK-3 2/4 0, 0, 5, 7 0/4 None
QRsP/OK-4 0/4 0, 0, 0, 0 0/4 None
QRsP/OK-5 1/4 0, 0, 0, 8 0/4 None
QRsP/OK-6 0/4 0, 0, 0, 0 0/4 None
QRsP/OK-7 1/4 0, 0, 0, 2 0/4 None
Total 7/28
e 0/28 None
a1 10
5 QR-32 tumour cells were coimplanted with gelatine sponge in normal mice to which oxykine or gliadin had been administered per os (10mgkg
 1) once daily
throughout the experiment.
bCulture cell lines were separately established from tumours arisen in each mouse.
cPo0.05 vs saline.
dIn a separate experiment, 1 10
6 cells of each
cell line were injected into mice. After 25 days, the mice were killed and metastatic nodules at the surface of lung were counted macroscopically. Incidences of lung metastasis
were evaluated as follows:
ePo0.001 vs lung-colonising incidence of saline-treated group.
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sinflammatory cells, because the tumour cell lines had been
established by culturing the cells from tumours arisen in
individual mice and were originally their metastatic potential is
examined in another normal syngeneic mice (Okada et al, 1992).
We established in vitro culture cell lines from the arising tumours
in the mice treated with oxykine, gliadin or saline, and designated
them as QRsP/OK, QRsP/GD and QRsP tumour lines, respectively.
As Table 1b shows, the lung metastasis incidence was significantly
low; only in seven out of 28 lungs had positive metastases
developed after i.v. injection of QRsP/OK tumour cell lines,
whereas 35 out of 39 lungs and 33 out of 35 lungs had positive
metastases after injection of QRsP/GD and QRsP tumour lines,
respectively (Po0.001). At the time of killing, there was no
evidence of typical spontaneous metastasis.
Table 4 shows that the number of colonies per lung and the lung
net weight, which indirectly represent metastatic nodules in the
lungs. They are significantly less in the mice with QRsP/OK
tumour lines than in those with other tumour lines (Po0.001).
Although there was no reduction of lung metastasis with control
vehicle or gliadin treatment, it was suppressed by administration
of oxykine (97% inhibition).
No obvious side effect brought by oxykine treatment
Subcutaneously injected gelatin sponge pieces into the mice with
administration of oxykine, gliadin, melon-SOD or saline were
removed and the exact number of infiltrated cells was counted per
gelatin sponge. Table 5 shows that there was no significant
difference among the groups. Then we stained the infiltrated cells
and determined their cell types by histological examination, we
found that oxykine and other compounds did not make differences
in the types of cells infiltrated into gelatin sponge.
The application of oxykine or gliadin (10mgkg
 1day
 1 for 27
days) did not cause either any obvious side effect such as weight
loss, or alteration in the appearance or behaviour of the tumour-
bearing mice during the observation period. The data of average
body weight are shown in Figure 1B. The values of the oxykine
group were not lower than those of the control group (gliadin- or
saline treated) throughout the experimental period. There were no
significant differences in the final body weight among the
treatments (Table 6). Moreover, no significant differences were
observed in weights of organs at autopsy either in absolute or ratio
to body weight values among the groups (Table 6).
DISCUSSION
In this study, we showed that an orally available SOD, named
oxykine, inhibited inflammation-promoted acquisition of meta-
static phenotype of weakly tumorigenic and nonmetastatic murine
fibrosarcoma cells without adverse side effect. We also observed
suppression of the primary tumour growth by the oxykine
treatment.
Several lines of evidence implicate a relationship between
induction of SODs in tumour cells and reversion of neoplastic
transformation or loss of the malignant phenotype including
metastatic property. From these, it has been hypothesised that
SOD can be a new tumour suppressor gene (Sykes et al, 1978;
Bravard et al, 1992; Safford et al, 1994). It is reported that
unbalanced overexpression of SOD protein modulates cellular
signal transduction cascades such as tumour –invasion-associated
matrix metalloproteases through transactivation of transcription
factor(s) (Wenk et al, 1999; Nelson et al, 2003). Manganese-
None
NBT
Saline Gliadin Oxykine A
B
C
G
G
Figure 2 Formazan staining of the tumour tissues from oxykine- and
gliadin-treated mice after perfusion with nitroblue tetrazolium (NBT).
Tumours were perfused with or without NBT (1mgml
 1), which was
followed by wash with Hank’s balanced salt solution to remove unreacted
NBT (A). The tumour tissues were fixed with zinc/formalin and stained
with haematoxylin/eosin. Shown is a typical section, indicating intense
deposition of formazan crystal (arrow heads). Tumour section obtained
from gliadin-treated mice (B) and oxykine-treated mice (C). G; gelatine
sponge filament. Bar; 10mm.
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Figure 1 Changes of tumour growth (A) and body weight (B) following
oxykine treatment. Tumour growth curves and body weight curves of
normal syngeneic C57BL/6 mice-bearing QR-32 tumour cells coimplanted
with a gelatine sponge. Oxykine (closed circle), gliadin (open circle) or
saline (open square) had been administered to the mice.
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ssuperoxide dismutase is known to be particularly high in primary
hepatoma (Taniguchi, 1992), gastric cancer (Taniguchi, 1992),
acute myeloid and/or lymphocytic leukaemias (Nishiura et al,
1992), epithelial-type ovarian cancer (Ishikawa et al, 1990), central
nervous system tumours (Cobbs et al, 1996) and neuroblastoma
(Kawamura et al, 1992); on the other hand, lower SOD levels have
generally been demonstrated in other tumour cells and clinical
tumour tissues (Oberley and Buettner, 1979; Loven et al, 1984;
Oberley and Oberley, 1988; Brorrello et al, 1993).
To date, eight different techniques have been established to
elevate SOD levels in tumour cells or tumour tissues. All the
techniques have been reported to reverse malignant phenotypes of
tumour cells. They are (i) intravenous or subcutaneous adminis-
tration of recombinant human SOD which substitutes specific
amino acid for stable one (Yoshizaki et al, 1994); (ii) intravenous
administration of SOD conjugated with a pyran copolymer, for
prolongation of its activity (Oda et al, 1989); (iii) addition of
exogenous liposomal SOD (Beckman et al, 1988); (iv) intra-
periponeal or subcutaneous administration of a selective SOD
mimetic molecule of nonpeptidic and low molecular weight
(Samlowski et al, 2003); (v) elevation of SOD level by sense cDNA
transfection (Safford et al, 1994); (vi) inoculation of fibroblasts
that are genetically modified to secrete SOD (Tanaka et al, 2001);
(vii) elevation of SOD levels by exposure to a superoxide generator
and subsequent isolation of superoxide-resistant cells (Fernandez-
Pol et al, 1982); (viii) secondary induction of SOD in tumour
Table 2 Activities of manganese, copper and zinc superoxide dismutases, catalase and glutathione peroxidase in serum or tumour tissues of mice orally or
intraperitoneally treated with oxykine, gliadin, melon SOD or saline
Antioxidative enzyme activities mg
 1 protein in
Tumour tissues Serum
Treatment
a Route of administration Mn-SOD (U) CuZn-SOD (U) Catalase (U) GPx (mU) Mn-SOD (U) CuZn-SOD (U)
Saline Per oral 2.371.2
b 12.973.0 36.274.0 78.3712.9 1.770.3 14.271.4
Gliadin Per oral 2.770.5 15.671.7 35.8711.8 79.578.7 1.770.5 14.270.4
Melon SOD Per oral 2.970.4 14.771.1 35.0712.1 79.8710.0 1.770.5 13.672.0
Oxykine Per oral 5.171.1
b 14.373.3 35.8725.8 77.3738.2 1.870.6 14.772.2
Saline Intraperitoneal 2.770.7 15.572.6 33.378.4 83.7739.0 2.371.2 13.971.5
Gliadin Intraperitoneal 2.270.8 13.872.7 28.578.6 66.6727.0 1.970.6 14.970.7
Melon SOD Intraperitoneal 2.970.4 14.970.7 30.376.7 85.5710.8 1.570.3 13.870.8
Oxykine Intraperitoneal 2.570.3 15.372.9 32.3712.4 83.372.5 2.771.2 12.372.1
a1 10
5 QR-32 tumour cells were coimplanted with gelatine sponge in normal mice to which oxykine, gliadin, melon SOD had been administered orally or intraperitoneally
(10mgkg
 1) every day from 2 days before coimplantation to the end of the experiment. All the mice were killed under ether anaesthesia at 28 days after implantation, and
serum and tumour tissues were collected for examination.
bPo0.01 vs saline group.
Table 3 Tumour development and acquisition of metastatic ability of QR-32 tumour cells were inhibited by oral administration of oxykin, but not by a
single component of oxykine formulation or by a different administration route
Incidence of tumorigenicity Incidence of metastasis
Treatment
a Route of administration
No. of mice with tumour take/no. of
mice treated (%)
No. of mice with lung metastasis/no. of
mice treated (%)
Saline Per oral 9/10 (90)
b 20/20 (100)
c
Gliadin Per oral 8/9 (89) 18/20 (90)
Melon SOD Per oral 9/10 (90) 18/20 (90)
Oxykine Per oral 4/10 (40)
b 5/19 (26)
c
Saline Intraperitoneal 10/10 (100) 18/20 (90)
Gliadin Intraperitoneal 8/10 (80) 19/20 (95)
Melon SOD Intraperitoneal 10/10 (100) 21/22 (95)
Oxykine Intraperitoneal 8/10 (80) 20/22 (91)
a1 10
5 QR-32 tumour cells were coimplanted with gelatine sponge in normal mice to which oxykine, gliadin or melon SOD had been administered orally or intraperitoneally
(10mgkg
 1) once daily throughout the experiment.
bPo0.05 vs saline.
c1 10
6 cells of each cell line established from the arising tumours were injected into mice. After 25 days,
the mice were killed and metastatic nodules at the surface of lung were counted macroscopically. Incidences of lung metastasis were evaluated as follows: Po0.001 vs lung-
colonising incidence of saline-treated group.
Table 4 Inhibition of QRsP/OK tumour lines’ acquisition of metastatic ability by oxykine
Cell lines Metastatic incidence (%) Lung weight (g) No. of lung metastatic nodules Medium value Range Per cent reduction
QRsP 33/35 (94)
a 0.4570.46
b 50.1761.5
a 12 0–150 0
QRsP/GD 35/39 (90) 0.3770.39 41.5755.9 15 0–150 17
QRsP/OK 7/28 (25)
a 0.1870.02
b 1.673.9
a 00 – 1 8 9 7
1 10
6 of tumour cells was injected intravenously into C57BL/6 mice. On day 25, the mice were killed and metastatic nodules at the lung surface were counted. Data represent
the mean7s.d.
aPo0.001.
bPo0.005 as compared to QRsP tumour cells.
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stissues by administration of an immunopotentiator which
stimulates immune cells to produce SOD-inducible cytokines such
as interferon-gamma and tumour necrosis factor-alpha (Habelhah
et al, 1998). There is no doubt that an orally available SOD would
be worth developing for preclinical use of SOD. However, in an
experiment using mice, only a small portion (approximately 10%)
of orally administered SOD is absorbed through gastrointestinal
tract (Giri and Misra, 1984), and most of it was digested, similarly
to other proteins, before being absorbed into the blood stream. As
a solution of this problem, SOD has been coated with a protective
vegetal prolamine (wheat gliadin) layer that not only prevents
gastric digestion (Vouldoukis et al, 2003) but also promotes the
delivery of the bioactive molecule in the mucosa of small intestine
(Clemente et al, 2003). In this study, we used cantaloupe melon
(Cucumis melo LC. Cucurbitaceae)-derived SOD. The C. melo LC.
derived SOD has an SOD activity which is more than five times
that of classical melon species, charentais (Vouldoukis et al, 2004).
In fact, melon, barley plant, broccoli, Brussels sprouts, cabbage,
wheat grass and most green plants which we have in daily meals
naturally contain large amounts of SOD. Kitagawa et al (1986,
1991) reported that X-ray crystallography of plant SOD showed a
high structural homology to the mammalian SOD, indicating
common characteristics beyond the species barrier such as
enzymatic activity (Taniguchi, 1992).
Niitsu and his colleagues have discovered an inhibitory effect of
SOD on both experimental and spontaneous pulmonary metastasis
in murine models (Yoshizaki et al, 1994). They intensively
investigated the mechanisms and reported that SOD dramatically
suppressed motility and invasion of both human and murine
tumour cells (Yoshizaki et al, 1994; Muramatsu et al, 1995). A
similar suppressive effect of SOD on tumour metastasis was
observed in the studies of exogenous and endogenous SOD
treatments (Kwee et al, 1991) and of SOD cDNA transfection
(Safford et al, 1994). Besides the direct inhibitory effect of SOD on
motile phenotype of tumour cells, our present study revealed
reduced acquisition of metastatic phenotype in the process of
tumour development. We can conclude that the effect we observed
was specific to the metastatic ability itself of tumour cells, because
we used the culture cell lines established for the evaluation of
metastatic ability and the culture condition excluded contamina-
tion of oxykine or inflammatory cells. As indicated by in situ
superoxide production levels in each treatment in Figure 2, we
believe that the oxykine administration dismutates superoxides
which are produced mainly by gelatine sponge-elicited inflamma-
tory cells and are known as a genotoxic substance to induce gene
alterations. From these, we speculate that oxykine may prevent
metastasis-associated gene alteration(s) caused by ROS produced
by inflammatory cells.
We also observed inhibition of the primary tumour growth in the
group with oxykine administration. There are three possible
explanations for this. One is that the elevated levels of SOD might
lower intracellular levels of O2
 , which in tern downmodulates signal
transduction and/or activation of transcription factors to suppress
cell growth (Burdon, 1995). Irani et al (1997) have recently shown
that superoxide acts especially as signal regulator for the stimulation
of cell growth through a flavoprotein and Rac1 pathways. Second is
that SOD might stimulate tumoricidal immune effector cells.
Samlowski et al (2003) demonstrated that administration of SOD
mimetic nonpeptidic molecule enhanced the cytotoxicity of
lymphokine-activated killer (LAK) cells in vivo. Indeed, the QR-32
tumour cells are highly sensitive to LAK cells (Okada et al, 1994).
Third is that oxykine might stimulate immune cells to produce
SOD-inducible cytokines and growth factors. Those factors would
coordinately synthesise de novo SOD at the tumour-growing sites. In
our experiments, we revealed that Mn-SOD was induced in tumour
cells only by oxykine formulation (Table 2). However, a single
component of the oxykine by itself, that is, gliadin alone or SOD
alone, does not have ability to induce SOD. At this time, we do not
know the precise mechanisms responsible for this, but speculate
that the oxykine formulation possibly activates the host immune
system besides exerting direct SOD action. Since the main
compound of melon-derived SOD induces Th1-dependent immu-
nity (Vouldoukis et al, 2003), and the compound covered with
gliadin has been identified as a major allergen for wheat-dependent
exercise-induced anaphylaxis (Matsuo et al, 2005), both compo-
nents seem to be immunogenic to host. Furthermore, only the oral
Table 5 Differential leukocyte counts and numbers of cells infiltrated into gelatin sponge in mice with per oral administration of oxykine, gliadin or saline
Percentage of differential leukocytes per gelatin sponge-infiltrated cells
Treatment
a
No. of
mice
examined
Total no. of gelatin
sponge-infiltrated
cells ( 10
5) Mø/MO PMN LC EOS Others
Saline 5 15.673.1 12.176.3 53.677.4 28.072.8 1.670.5 3.172.4
Gliadin 6 19.375.8 9.972.0 49.776.0 26.872.7 1.671.5 5.070.8
Melon SOD 6 19.075.8 13.174.2 50.673.1 30.772.9 1.471.8 4.873.7
Oxykine 6 18.472.7 8.674.2 53.575.4 30.872.9 1.671.1 4.572.3
Mø/MO, macrophages/monocytes; PMN, polymorphonuclear neutrophils; LC, lymphocytes; EOS, eosinophils.
aA piece of gelatine sponge was implanted into the subcutaneous
space of normal mice to which oxykine, gliadin or melon-SOD had been administered orally (10mgkg
 1) once daily for 5 days.
Table 6 Averages of final body weights and absolute/relative organ weights of mice treated with oxykine, gliadin or saline administered
Liver weight Kidney weight
b Lung weight
Treatment
No. of mice
examined
Final body
weight Absolute (g) Relative (%)
a Absolute (g) Relative (%)
a Absolute (g) Relative (%)
a
Saline 19 20.671.1 1.0470.19 5.170.8 0.2970.08 1.470.4 0.1870.03 0.970.1
Gliadin 18 19.871.7 1.0070.15 5.070.8 0.3170.09 1.670.5 0.1970.05 1.070.3
Oxykine 17 20.771.4 1.1070.19 5.471.1 0.3670.10 1.770.4 0.2270.05 1.070.2
The mean values of body weight in the groups showed no significant decreases compared with that of the saline-group throughout the experimental period.
aRelative organ
weight¼organ net weight/body weight (%).
bCombined weight of the two kidneys.
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sadministration was effective on the induction of SOD and
suppression of the tumour progression phenotype (Table 3).
Therefore, immunopotentiating effects of orally administered
oxykine maybe involved in augmentation of immune system of
intestinal tract or whole body through absorption via gastro-
intestinal tract. We are currently undertaking a study to determine
whether oxykine has a role in activation of immune functions.
The formation of human cancer involves a multistage process,
that is, initiation, promotion and tumour progression. Oxidative
stress is considered to contribute to the whole process from
carcinogenesis through induction of mutations or upregulation of
cell growth in target cells (Okada, 2002). In this study, we showed
inflammation-promoted tumour progression was prevented by
administration of a SOD derivative, oxykine. Recent reports have
verified that oxykine protects cells from hyperbaric oxygen-
induced oxidative stress, that is, breaks of DNA strand in healthy
volunteers (Muth et al, 2004) and that oxykine prevents oxidative
stress-mediated diabetic nephropathy in rodent model of type 2
diabetes (Naito et al, 2005). This orally available molecule will be
effective in clinical utilisation to prevent both tumour development
and progression.
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